Will expand capacity to produce active pharmaceutical ingredients for a growing number of diabetes drugs under development
Novo Nordisk is increasing its drug development capacity by investing DKR550m (US$100m) in a new research and development facility in Bagsværd, Denmark. The purification plant will expand the company’s capacity to produce active pharmaceutical ingredients for a growing number of diabetes drugs under development.
The pilot plant will be fully operational by late 2016 and will be run by CMC Supply (Chemistry, Manufacturing and Control Supply); a unit within Novo Nordisk R&D. CMC Supply develops, produces and formulates all new protein and peptide processes in Novo Nordisk.
'The new purification pilot plant will significantly increase our capacity for early-phase diabetes projects,' said Jesper Bøving, senior vice president, CMC Supply. 'It will create up to 35 new jobs over a two-year period in addition to the 100 new employees CMC Supply will hire in Denmark in 2014.'
The project initially involves establishment of a pilot plant with one purification line. The facility can be expanded to double the size to further increase the capacity. In total 5km of steel pipes will be used in the purification pilot plant with a total area of 2,700m2.